Semaglutide is an agonist of glucagon-like peptide 1 receptor (GLP-1R). It is a glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of type 2 diabetes mellitus. It has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and is derivatised at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was lesser compared to liraglutide, whereas the albumin affinity was increased. It lowers blood glucose by stimulating the release of insulin and also lowers body weight. It is long-acting, with an extended half-life of approximately 1 week.